← Back to Search

Ultrasound Therapy

Transcranial MRgFUS for Parkinson's Disease

N/A
Waitlist Available
Led By Jeff Elias, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12-months post treatment

Summary

This trial is to see if a new treatment for Parkinson's disease is safe.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12-months post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12-months post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of adverse events
Mean change in MDS-UPDRS Part III scores
Secondary study objectives
Long Term Adverse Events Profile
Other study objectives
Mean change in MDS-UPDRS Part IV scores
Mean change in MDS-UPDRS total score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExAblate Treated ArmExperimental Treatment1 Intervention
ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
Group II: ExAblate Sham Treated ArmPlacebo Group1 Intervention
ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ExAblate Transcranial System
2011
N/A
~30

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
91 Previous Clinical Trials
3,791 Total Patients Enrolled
Jeff Elias, MDPrincipal InvestigatorUniversity of Virginia
1 Previous Clinical Trials
12 Total Patients Enrolled

Media Library

ExAblate Transcranial System (Ultrasound Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02246374 — N/A
Parkinson's Disease Research Study Groups: ExAblate Sham Treated Arm, ExAblate Treated Arm
Parkinson's Disease Clinical Trial 2023: ExAblate Transcranial System Highlights & Side Effects. Trial Name: NCT02246374 — N/A
ExAblate Transcranial System (Ultrasound Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02246374 — N/A
~1 spots leftby Nov 2025